<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645073</url>
  </required_header>
  <id_info>
    <org_study_id>M03-628</org_study_id>
    <nct_id>NCT00645073</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis</brief_title>
  <official_title>A Phase IV Comparative Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy of a ten-day course of therapy of cefdinir, 600 mg QD, to&#xD;
      a ten-day course of therapy of levofloxacin, 500 mg QD, in the treatment of acute bacterial&#xD;
      sinusitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic response</measure>
    <time_frame>26 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in clinical signs and symptoms</measure>
    <time_frame>26 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Acute Bacterial Sinusitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefdinir (Omnicef)</intervention_name>
    <description>Two 300 mg cefdinir capsules on Study Days 1-10.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>ABT-198</other_name>
    <other_name>Omnicef</other_name>
    <other_name>cefdinir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin</intervention_name>
    <description>Two 250 mg levofloxacin capsules on Study Days 1-10</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A female must be non-lactating, non-breastfeeding and at no risk for pregnancy.&#xD;
&#xD;
          -  A condition of general good health, based upon the results of a medical history,&#xD;
             physical examination, and laboratory profile.&#xD;
&#xD;
          -  Subject must have a diagnosis of acute bacterial sinusitis. The diagnosis must be&#xD;
             based on the following:&#xD;
&#xD;
               -  a sinus radiograph or CT scan performed within 48 hours pre-treatment&#xD;
&#xD;
               -  with evidence of maxillary opacification or air/fluid levels&#xD;
&#xD;
          -  Purulent discharge from the nose&#xD;
&#xD;
          -  At least one of the following clinical signs and symptoms of acute bacterial sinusitis&#xD;
&#xD;
               -  Lasting for more than 7 days prior to and no longer than 21 days before&#xD;
                  Evaluation 1: facial pain over the sinus or facial pressure over the sinus or&#xD;
                  facial tightness over the sinus or facial swelling or toothache.&#xD;
&#xD;
          -  Subject must be a suitable candidate for oral antimicrobial therapy and is able to&#xD;
             swallow capsules intact.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have: chronic sinusitis (signs and symptoms lasting greater than 28 days&#xD;
             prior to Evaluation 1)&#xD;
&#xD;
          -  Significant anatomical abnormalities of the sinuses&#xD;
&#xD;
          -  Any other infection or condition which necessitates use of a concomitant systemic&#xD;
             antimicrobial.&#xD;
&#xD;
          -  History of any hypersensitivity or allergic reactions to penicillins, cephalosporins&#xD;
             (including cefdinir), or quinolones (including levofloxacin).&#xD;
&#xD;
          -  Subject who has taken: a systemic antibiotic within 14 days before study drug&#xD;
             administration; a long acting injectable antibiotic (e.g., penicillin G benzathine)&#xD;
             within 30 days before study drug administration.&#xD;
&#xD;
          -  Known significant renal or hepatic impairment.&#xD;
&#xD;
          -  Evidence of uncontrolled clinically significant cardiovascular, pulmonary, metabolic,&#xD;
             gastrointestinal, neurological or endocrine disease, malignancy, or other abnormality&#xD;
             (other than the disease being studied).&#xD;
&#xD;
          -  Investigator considers the subject unsuitable for cefdinir or levofloxacin therapy,&#xD;
             for any reason.&#xD;
&#xD;
          -  Previous enrollment in this study.&#xD;
&#xD;
          -  Any underlying condition or disease state that would interfere with the completion of&#xD;
             the study procedures and evaluations or absorption of study drug.&#xD;
&#xD;
          -  Subject who is currently receiving or who is likely to require any of the following&#xD;
             medications during the period between Evaluation 1 (initial presentation to&#xD;
             office/clinic) and Evaluation 3 (or within 48 hours after the last dose of study&#xD;
             drug): Concomitant theophylline or any theophylline analog, unless plasma levels of&#xD;
             these drugs can be adequately monitored during the study; Warfarin and probenecid.&#xD;
&#xD;
          -  Immunocompromised subjects.&#xD;
&#xD;
          -  Subject who requires parenteral antibiotic therapy for this infection or who has any&#xD;
             other infection or condition, that necessitates use of a concomitant systemic&#xD;
             antibiotic.&#xD;
&#xD;
          -  Subjects receiving antacids containing magnesium, or aluminum, as well as sucralfate,&#xD;
             metal cations such as iron, and multivitamin preparations with zinc within 2 hours&#xD;
             before or after dosing with study drug.&#xD;
&#xD;
          -  Subjects with a known or suspected central nervous system disorder that may predispose&#xD;
             the subject to seizures or lower the seizure threshold.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbiana</city>
        <state>Alabama</state>
        <zip>35051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eclectic</city>
        <state>Alabama</state>
        <zip>36024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murray</city>
        <state>Kentucky</state>
        <zip>42071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portage</city>
        <state>Michigan</state>
        <zip>49024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <state>Tennessee</state>
        <zip>38358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gorzow Wielkopolski</city>
        <zip>66-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>92-215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Przybyslawice</city>
        <zip>322-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <zip>70-344</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <zip>70-506</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <zip>71-667</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 22, 2008</study_first_submitted>
  <study_first_submitted_qc>March 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>March 22, 2008</last_update_submitted>
  <last_update_submitted_qc>March 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>Angela M Nilius, PhD</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Acute Bacterial Sinusitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Cefdinir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

